Jake Shortt

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Simon J. Hogg, Stephin J. Vervoort, Sumit Deswal et al. · Cell Reports · 2017 · 296 citations · Full text

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Marta Chesi, Geoffrey M. Matthews, Victoria M. Garbitt et al. · Blood · 2012 · 207 citations

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

Simon J. Hogg, Olga Motorna, Leonie A. Cluse et al. · Molecular Cell · 2021 · 157 citations · Full text

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 154 citations · Full text

Hematological Malignancy, Thrombosis, Interim Analysis +12

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Michael Bots, Inge Verbrugge, Benjamin P. Martin et al. · Blood · 2014 · 133 citations · Full text